Evidence map›Paper›PMID 33859239›Full record

ArticleScientific reports2021

Novel, non-invasive markers for detecting therapy induced neuroendocrine differentiation in castration-resistant prostate cancer patients.

Divya Bhagirath, Michael Liston, Theresa Akoto, Byron Lui, Barbara A Bensing, Ashok Sharma, Sharanjot Saini

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 3 pooled it
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 3 syntheses or guidelines pooled it, 67 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Divya BhagirathDepartment of Biochemistry and Molecular Biology, Augusta University, 1410 Laney Walker Boulevard, Augusta, GA, 30912, USA.
Michael ListonVeterans Affairs Medical Center, San Francisco, USA.
Theresa AkotoDepartment of Cellular Biology and Anatomy, Augusta University, Augusta, USA.
Byron LuiVeterans Affairs Medical Center, San Francisco, USA.
Barbara A BensingVeterans Affairs Medical Center, San Francisco, USA.
Ashok SharmaDepartment of Population Health Sciences, Augusta University, Augusta, USA.
Sharanjot SainiDepartment of Biochemistry and Molecular Biology, Augusta University, 1410 Laney Walker Boulevard, Augusta, GA, 30912, USA. ssaini@augusta.edu.
Augusta University · USSan Francisco VA Medical Center · USAugusta University Health · US

Funding

MicroRNAs in frequently deleted loci regulate prostate cancer EMT and metastasisR01CA177984 · NCI · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI SAINI, SHARANJOT · 2014 to 2018
$1.9M
NCI NIH HHS R01 CA177984
6 · The paper itself

Abstract

Neuroendocrine prostate cancer (NEPC), a highly aggressive variant of castration-resistant prostate cancer (CRPC), often emerges upon treatment with androgen pathway inhibitors, via neuroendocrine differentiation. Currently, NEPC diagnosis is challenging as available markers are not sufficiently specific. Our objective was to identify novel, extracellular vesicles (EV)-based biomarkers for diagnosing NEPC. Towards this, we performed small RNA next generation sequencing in serum EVs isolated from a cohort of CRPC patients with adenocarcinoma characteristics (CRPC-Adeno) vs CRPC-NE and identified significant dysregulation of 182 known and 4 novel miRNAs. We employed machine learning algorithms to develop an 'EV-miRNA classifier' that could robustly stratify 'CRPC-NE' from 'CRPC-Adeno'. Examination of protein repertoire of exosomes from NEPC cellular models by mass spectrometry identified thrombospondin 1 (TSP1) as a specific biomarker. In view of our results, we propose that a miRNA panel and TSP1 can be used as novel, non-invasive tools to identify NEPC and guide treatment decisions. In conclusion, our study identifies for the first time, novel non-invasive exosomal/extracellular vesicle based biomarkers for detecting neuroendocrine differentiation in advanced castration resistant prostate cancer patients with important translational implications in clinical management of these patients that is currently extremely challenging.

Indexed as

Extracellular VesiclesBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsBiomarkers, TumorCarcinoma, NeuroendocrineCell Line, TumorHigh-Throughput Nucleotide SequencingHumansMachine LearningMaleMicroRNAsProstatic Neoplasms, Castration-ResistantBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsBiomarkers, TumorMicroRNAsSPZ1 protein, human

Identifiers

PMID33859239
PMCPMC8050049
OpenAlexW3153815680

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.